epidermolysis bullosa

EB’s great hopePediatricians respond to the first successful gene therapy treatment for epidermolysis bullosa.
Protuberant blister over newborn’s lumbar spineA healthy full-term newborn presented with a prominent sacral dimple within an oval patch. Ultrasound showed no evidence of spinal anomalies, and the child was discharged home. Three days later, the patch became elevated, red, and moist appearing, and she was brought to the emergency department (ED) for further evaluation of the “growing blister.”
Pipeline topical reduces epidermolysis bullosa blisteringCastle Creek Pharmaceuticals announced in June 2017 that the first patient had enrolled in its phase 2/3 study assessing the safety and efficacy of its pipeline diacerein 1% ointment to treat epidermolysis bullosa simplex.
Hope for butterfly children
Hope for butterfly childrenEpidermolysis bullosa (EB) is often described as ‘the worst disease you’ve never heard of,’ and the young sufferer of this condition are referred to as ‘butterfly children’ because their skin is said to be fragile as the wings of butterflies. A potential new topical treatment option, in phase 3 trials, could help to change the EB treatment landscape.
EB drug has significant medical, market potentialScioderm Inc. has released data from its recently completed phase 2b clinical trial — and plans for a phase 3 trial — on its investigational therapy Zorblisa (SD-101), a topical treatment for blistering and lesions associated with epidermolysis bullosa (EB). Read to learn more
Epidermolysis bullosa presents unique woundcare challengesIt’s advisable for clinicians to release the fluid in blisters that develop in children with epidermolysis bullosa (EB), but they should aim to keep the roof of the blister intact, an expert recommends.